logo-loader
viewVolitionRx

VolitionRx to present Nu.Q coronavirus study data at MEDICA 2020 virtual forum

The presentation will outline the company's Nu.Q Nucleosomics technology’s ability to identify cell free circulating nucleosomes in at-risk individuals with COVID-19

Coronavirus graphic
Data from two independent cohorts of COVID-19 patients with quantitative nucleosome immunoassays showed that nucleosomes were highly elevated in the plasma of patients with severe COVID-19

VolitionRx Limited (NYSEAMERICAN:VNRX) will present preliminary results from its proof of concept clinical studies focused on monitoring disease progression of COVID-19 as part of the "Innovative COVID-19 Diagnostics" session at today's virtual MEDICA LABMED Forum.

The presentation, "Circulating nucleosomes as potential prognostic markers for COVID-19 disease severity" will outline the company's Nu.Q Nucleosomics technology’s ability to identify cell free circulating nucleosomes associated with elevated NETosis — the body's immune response to an infection — in at-risk individuals with COVID-19.

Volition’s initial studies demonstrated that symptomatic COVID-19 patients have elevated circulating nucleosomes. As a result, the company has filed a patent for monitoring disease progression of COVID-19 and other NETosis associated infections. 

READ: VolitionRx ends 3Q with $21M in cash as it prepares to launch Nu.Q Vet Cancer Screening Test

Data from two independent cohorts of COVID-19 patients with quantitative nucleosome immunoassays showed that nucleosomes were highly elevated in the plasma of patients with severe COVID-19, relative to healthy control subjects.

The highest levels of nucleosomes were found in patients requiring artificial ventilation or extracorporeal oxygenation. Volition believes that nucleosomes could be used to monitor disease progression in COVID-19 patients and potentially other diseases such as influenza and sepsis.

The early identification and triaging of at-risk COVID-19 patients to determine those most likely to deteriorate and require critical care would enable both improved outcomes for patients and a more efficient use of critical care resources for healthcare providers, the company said. 

The presentation will be led by Volition founding scientist and business director Mark Eccleston.

"We are very pleased to be invited to present data at the MEDICA LABMED Forum on the work we are doing to use circulating nucleosomes to monitor COVID-19,” Eccleston said in a statement. “As we see the number of cases rise again worldwide, we believe more than ever that the ability to understand disease progression and to manage resources accordingly is an important and still unmet need. We look forward to announcing further data soon."

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: VolitionRx

Price: 3.38 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $162.91 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx Limited ends its 3Q with $21M in the bank, looks forward to...

VolitionRx Limited (NYSE AMERICAN:VNRX) CEO Cameron Reynolds tells Proactive the group finished its third quarter with around $21M in the bank compared with $17M at the end of 2019. Reynolds also discussed upcoming milestones including the preparing to launch its new product, Nu.Q™ Vet Cancer...

2 weeks, 1 day ago

2 min read